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Abstract 
Background: Traumatic bone fractures cause moderate to severe pain, which needs to be minimized for optimal 
recovery and animal welfare, illustrating the need for reliable objective pain biomarkers for use in a clinical setting. The 
objectives of this study were to investigate catestatin (CST) and vasostatin (VS) concentrations as two new poten‑
tial biomarkers, and cortisol concentrations, scores of the short form of the Glasgow composite measure pain scale 
(CMPS‑SF), and visual analog scale (VAS) in dogs suffering from traumatic bone fractures before and after morphine 
administration in comparison with healthy dogs.
Methods: Fourteen dogs with hind limb or pelvic fractures and thirty healthy dogs were included. Dogs with frac‑
tures were divided into four groups according to analgesia received before participation. Physical examination, CMPS‑
SF, pain and stress behavior VAS scores were recorded in all dogs. Saliva and blood were collected once in healthy 
dogs and in dogs with fractures before and 35–70 min after morphine administration. Blood samples were analyzed 
for CST, VS, and cortisol. Saliva volumes, however, were insufficient for analysis.
Results: Catestatin and cortisol concentrations, and CMPS‑SF, and VAS scores differed significantly between dogs 
with fractures prior to morphine administration and healthy dogs. After morphine administration, dogs with fractures 
had significantly decreased CMPS‑SF and VAS scores and, compared to healthy dogs, CST concentrations, CMPS‑SF, 
and VAS scores still differed significantly. However, CST concentrations remained largely within the normal range. 
Absolute delta values for CST significantly correlated with delta values for CMPS‑SF. Catestatin and cortisol did not 
differ significantly before and after morphine administration. Vasostatin concentrations did not differ significantly 
between groups.
Conclusions: Catestatin and cortisol concentrations, CMPS‑SF, and VAS scores differed significantly in the dogs 
with traumatic bone fractures compared to the healthy dogs. Morphine treatment partially relieved pain and stress 
according to the subjective but not according to the objective assessments performed. However, because of the large 
degree of overlap with normal values, our results suggest that plasma CST concentrations have a limited potential as 
a clinically useful biomarker for pain‑induced stress.
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Background
Traumatic bone fractures occur commonly in dogs, often 
requiring both analgesia and surgery as a part of the 
treatment. The pain level induced by bone fractures is 
reported to be moderate to severe and opioids have been 
shown to be the analgesia of choice [1, 2]. It is essential to 
provide sufficient pain relief for animal welfare reasons, 
and to reduce recovery time and duration of hospitaliza-
tion [3]. The perception of pain varies between individu-
als [4]. Therefore, proper assessment of each patient is 
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necessary for optimal analgesia administration. However, 
pain evaluation is a challenging task because all currently 
available assessment methods have limitations, and no 
one method has been found to be optimal for all animals 
[2, 5].
Pain evaluation can be performed by using subjec-
tive assessment methods, e.g. observation of behaviors, 
and by measuring objective physiological and hormo-
nal parameters that are influenced by a neuroendocrine 
stress response. Several subjective pain assessment tools 
have been used in dogs and cats: for example, simple 
descriptive scores (SDS), numeric rating scales (NRS), 
visual analog scales (VAS), Glasgow composite meas-
ure pain scales (CMPS), and short form of the Glasgow 
composite measure pain scales (CMPS-SF) [5–10]. The 
CMPS and the CMPS-SF combine several subjective 
behaviors for assessment of acute pain, and both have 
been validated for use in dogs [8, 11].
Several physiological parameters change in response 
to activation of a neuroendocrine stress response char-
acterized by stimulation of the hypothalamic-pituitary-
adrenal (HPA) axis and the sympatho-adrenal-medullary 
(SAM) axis [12, 13] such as heart rate, respiratory rate, 
blood pressure, and blood glucose, cortisol, and catecho-
lamines concentrations [14]. Although unspecific, these 
parameters have long been used in studies on pain and 
stress response in animals, alone or in combination with 
other parameters [13, 15, 16].
Measurement of cortisol has traditionally been used 
as an indicator for increased stress or pain. However, in 
addition to stress, plasma cortisol concentrations vary 
considerably over time due to pulsatile secretion, and 
there may be an influence from circadian rhythm [17–
20]. Therefore, the usefulness of plasma cortisol as a sole 
biomarker in a clinical setting is limited. Still, until better 
biomarkers are found, measurement of cortisol concen-
trations remains important in studies on stress [21, 22].
Although catecholamines increase promptly after 
SAM stimulation, they have a short half-life and are rap-
idly degraded, which limits their usefulness in a clinical 
setting [23]. Chromogranin A (CgA) has recently been 
suggested as an alternative marker for SAM activation. 
Chromogranin A is a glycoprotein, which is co-released 
with catecholamines and other neuroendocrine hor-
mones such as adrenaline, noradrenaline, dopamine, and 
neuropeptides [24, 25]. Concentration of CgA is rather 
stable for handling and storage compared to catechola-
mines with longer circulating half-life of 18 min [25–27].
CgA concentrations are increased in patients with 
enterochromaffin-like cell hyperplasia in the gastric 
mucosa which can be seen in atrophic gastritis with Heli-
cobacter pylori infection, and in conjunction with pro-
ton pump inhibitor treatment [28–30]. In the absence 
of neuroendocrine tumors and gastrointestinal disease, 
plasma CgA concentration is considered to reflect the 
activity of the SAM axis. In human studies, CgA meas-
urements in saliva and plasma have shown promise as 
potential biomarkers for stress [31–39]. In dogs, only a 
few studies on CgA have so far been published [40–47]. 
Chromogranin A can be measured in dogs and cats by 
estimating the CgA epitopes catestatin (CgA 361–372; 
CST) and vasostatin (CgA 17–38; VS) using radioimmu-
noassay (RIA) [43]. We have previously established nor-
mal reference ranges for plasma CST and VS using RIA 
in healthy dogs accustomed to sampling procedures and 
investigated the correlation between CST and VS [48]. 
Plasma CST and VS and saliva CST concentrations have 
been shown not to be affected by circadian, age, gender, 
or breed variations [41, 48].
In order to evaluate the usefulness of the CgA epitopes 
CST and VS as clinical biomarkers for pain-induced 
stress in dogs, studies performed in dogs that are expe-
riencing acute pain are needed. The objectives of this 
study were to investigate CST and VS concentrations as 
two new potential biomarkers, and cortisol concentra-
tions, scores of the CMPS-SF, and VAS in dogs suffering 
from traumatic bone fractures before and after mor-
phine administration in comparison with healthy dogs. 
We hypothesized that the concentrations of CST and VS 
should differ between healthy dogs and dogs with trau-
matic bone fractures before as well as after morphine 
administration. Furthermore, we hypothesized that the 
changes in CST and VS concentration would agree with 
other stress and pain assessments.
Methods
Study design and ethical approval
This study was designed as a prospective clinical study 
and was approved by Khon Kaen University Ethical Legis-
lation (AEKKU 26/2557). The study was performed dur-
ing March to June 2015. The dog owners were informed 
and gave their consent prior to participation. All dogs 
were admitted and treated according to the routines at 
Khon Kaen University (KKU) Veterinary Teaching Hos-
pital, Khon Kaen, Thailand. Participation in this study did 
not, in any manner, delay morphine administration to the 
dogs with bone fractures.
Dogs
Dogs with traumatic bone fractures
All dogs in the study were client-owned. Both primary 
and referral cases with traumatic bone fractures limited 
to the hind limbs and pelvis were included. On the day of 
admission, a standardized complete physical examination 
was performed in all dogs. Blood screening (hematol-
ogy and blood biochemistry) for evaluation of the overall 
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health status was performed according to the routines at 
KKU Veterinary Teaching Hospital [46]. Additionally, the 
dogs’ health status were classified in accordance with the 
American Society Anesthesiologists (ASA) Physical Sta-
tus Classification System [49, 50]. Dogs with traumatic 
ASA scores exceeding II, other concurrent disease, or 
that had received corticosteroid or proton pump inhibi-
tor therapy were excluded from the study.
All dogs with bone fractures that fulfilled the inclu-
sion criteria and, based on history taking at the time 
of admission, had a time lapse up to 4 days from injury 
and a withdrawal period from previous analgesia over 
6  h were included. Dogs were grouped, according to 
cause of trauma, duration of fracture, fracture site and 
number of bone fractures, previous analgesia, and with-
drawal period from previous analgesia. Dogs with trau-
matic bone fractures received a prompt paralumbar 
intramuscular injection with 0.5  mg/kg morphine sul-
fate (Morphine Sulfate injection, M & H manufacturing, 
Samutprakan, Thailand). Blood and saliva samples were 
collected immediately before and 35–70 min after mor-
phine administration.
Healthy dogs
Client-owned healthy dogs admitted for elective ovario-
hysterectomy were included as a control group. Data 
from these dogs were obtained from a previous study on 
CST and VS in dogs undergoing ovariohysterectomy [46]. 
Preoperative physical examination and blood screen-
ing were performed, in the same manner as for the dogs 
with bone fractures, to confirm a healthy status prior to 
inclusion in the study. Only dogs with ASA scores I with 
no other concurrent disease and that had not received 
steroid or proton pump inhibitor therapy were included. 
Samples and data were collected prior to surgery and 
preoperative medication on the day of surgery as previ-
ously described [46].
Method and sample protocol
The physical examination, assessments of CMPS-SF and 
overall pain score using VAS (OP-VAS), saliva and blood 
sample collection, and scoring of stress behavior using 
VAS (S-VAS) were performed on each sampling occasion. 
The order of sample collection was randomized, with an 
interval between saliva and blood sampling of less than 
5  min. In dogs with fractures, blood and saliva samples 
were collected immediately before and 35–70  min after 
morphine administration, as earlier described. All sam-
pling and assessments included in the study were per-
formed prior to any surgery. In healthy dogs, samples 
were collected once before any premedication on the day 
of surgery.
Subjective pain and stress assessment
In association with each sample collection, pain was 
scored using the CMPS-SF [11] and VAS for pain (OP-
VAS), in which one end of the scale indicated no pain and 
the other end referred to the worst possible pain. In dogs 
with traumatic bone fractures, section B of the CMPS-SF 
was not performed because all dogs had mobility prob-
lems and, therefore, the total score of the CMPS-SF was 
20. A score of 5 or more indicated the need of analgesia.
The stress behavior level was assessed during each 
saliva and blood sampling occasion using S-VAS [48] by 
observing avoidance behaviors during sample collection. 
Pre-established criteria, modified from Norling et  al. 
[51], were used for determination of stress levels during 
sampling (as illustrated in Fig. 1). All subjective pain and 
stress assessments were performed by the same observer 
(TS).
Saliva and blood collection
Saliva was collected using a swab, sized 8  ×  125  mm, 
(SalivaBio Children’s swab, Salimetrics, PA, USA) which 
was placed into the buccal cavity for 90 s. The swab was 
thereafter transferred to a 17  ×  100  mm swab storage 
tube (Swab storage tubes, Salimetrics, PA, USA) and cen-
trifuged at 3000  rpm (1401g) for 15  min. The swab was 
subsequently removed and the saliva deposit stored at 
−20 °C.
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Fig. 1 Stress behavior visual analog scale (S‑VAS). 1a Criteria used for 
evaluation of stress behavior during saliva sampling. 1b Criteria used 
for evaluation of stress behavior during blood sampling. The criteria 
of the S‑VAS [48] was modified from Norling et al. [51]
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Blood samples were collected from the distal cephalic 
vein using butterfly needles (BD Vacutainer, Becton-
Dickson, Plymouth, United Kingdom) into vacuum 
lithium heparin tubes and clot activator tubes (BD Vacu-
tainer, Becton-Dickson, Plymouth, United Kingdom). 
The tubes were centrifuged at 3300  rpm (1695  g) for 
5 min. The heparinized plasma and serum obtained was 
transferred into cryotubes (Low Temperature Freezer 
Vials, VWR, Stockholm, Sweden) and stored at −20 °C.
After the clinical part of the study was completed, all 
samples were transported to the Swedish University of 
Agricultural Sciences (SLU), Uppsala, Sweden, by a pri-
vate transportation company (Temperature control, 
World Courier, Bangkok, Thailand), and arrived within 
48  h. During transportation, the temperature was con-
trolled, monitored and remained below −20  °C. After 
arrival at SLU, the samples were freeze stored at −70 °C 
until analysis within a maximum of 7 months after 
collection.
Catestatin and vasostatin analysis
Concentrations of CST and VS were analyzed in saliva 
and plasma samples using rabbit antibodies against the 
human CgA amino acid sequence 17–38 for VS and 
sequence 361–372 for CST. Samples were analyzed in 
duplicate by competitive RIA at  the Clinical Chemistry 
Laboratory, Uppsala University Hospital, Uppsala, Swe-
den as earlier described [43]. The overall coefficient of 
variation (CV) in this study was <10%.
Cortisol analysis
Serum cortisol concentrations were analyzed in dupli-
cate. The analysis, using a solid-phase competitive chemi-
luminescent enzyme immunoassay (Immulite 2000, 
Siemens, Erlangen, Germany), was performed at the 
Clinical Chemistry Laboratory, University Animal Hospi-
tal, SLU, Uppsala, Sweden. The intraassay CV was  <5%. 
The limit of detection for cortisol analysis was 10 nmol/L. 
Samples with a concentration lower than the detection 
limit were recorded as 5 nmol/L.
Statistical analysis
In all analyses, residuals were checked for normality and 
homoscedasticity using diagnostic plots. Because the 
plasma VS values appeared skewed, this variable was log 
transformed (natural log) prior to analysis. For all vari-
ables, comparisons between healthy dogs and dogs with 
traumatic bone fractures were made using independent 
samples t tests. Comparisons of values before and after 
morphine administration in dogs with traumatic bone 
fractures were made using mixed linear models with 
“dog” as a random factor; this is analogous to a paired t 
test. Pairwise comparisons were adjusted for multiplicity 
using Tukey’s method. Similar analyses were also made to 
assess the effects of analgesia received before participa-
tion in the study, cause of trauma (unknown or car acci-
dent), duration of fracture (<48 or  ≥48  h), site (femur, 
tibia, both femur and tibia, or pelvis) and number of bone 
fractures (1–7), and withdrawal period from previous 
analgesia (≤12 or >12 h).
Delta values for CMPS-SF, OP-VAS, serum corti-
sol, and plasma CST concentrations were calculated by 
subtracting post treatment values/scores from baseline 
values prior to morphine treatment. Delta values with-
out +  or − signs were defined as absolute delta values. 
The correlation of analgesia group, the delta values for 
CMPS-SF, OP-VAS scores and the absolute delta values 
for serum cortisol and plasma CST concentrations were 
calculated using Proc corr.
All analyses were performed using SAS (2015) software 
[52]. Respiratory rates for panting dogs were recorded 
as 200 per minute. The selected level of significance was 
p < 0.05.
Results
Fourteen intact dogs with bone fractures limited to the 
hind limbs and pelvis and thirty intact healthy dogs 
admitted for elective ovariohysterectomy were included 
in the study. Mean  ±  SD age, body weight, and body 
condition scores of the included dogs are illustrated in 
Table 1.
The healthy dogs were all females of different breeds 
including Chihuahua (n  =  2), Thai Ridgeback (n  =  1), 
Thai Bangkaew (n =  1), Pomeranian (n =  3), Shih Tzu 
(n = 1), Maltese (n = 1), Siberian Husky (n = 1), Labra-
dor Retriever (n = 1), Poodle (n = 1), and Mixed Breeds 
(n = 18). Five of the dogs with fractures were females and 
nine males of different breeds including Pitbull (n = 2), 
Golden Retriever (n  =  3), Labrador Retriever (n  =  1), 
Pomeranian (n  =  1), and Mixed Breeds (n  =  7). The 
fractures were caused by traffic accidents (n = 12) or by 
unknown trauma (n = 2). The average (mean ± SD) dura-
tion of bone fracture injury prior to inclusion in the study 
was 46 ± 29 h. The fracture location was femur in seven 
Table 1 Age, weight, and body condition scores in 14 dogs 
with fractures and 30 healthy dogs
Data presented as mean ± SD
Parameters Dogs with traumatic  





Age (months) 12 ± 16 28 ± 26
Body weight (kg) 19.0 ± 9.7 11.6 ± 7.0
Body condition score (9 
grade scale)
6 ± 1 5 ± 1
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dogs (one fracture in five dogs and two fractures in two 
dogs), tibia in four dogs (one fracture in three dogs and 
two fractures in one dog), both femur and tibia in one 
dog (in total two fractures), and pelvis in two dogs (five 
and seven fractures respectively). They were allocated 
into four groups according to analgesia received before 
participation as follows; no analgesia (n = 3), unknown/
not specified analgesia (n  =  3), carprofen (n  =  4), or 
morphine (n = 4) (Table 2). The general attitude from the 
physical examinations varied from responsive (n  =  40) 
to depressed (n = 4). The blood screening results in the 
dogs with bone fractures showed leukocytosis with mild 
neutrophilia (n  =  7) whereas the results in the healthy 
dogs were all within the reference ranges.
Mean ± SD of the CMPS-SF, OP-VAS, and saliva and 
blood sampling S-VAS scores, temperature, heart rate, 
respiratory rate, concentrations of serum cortisol, and 
plasma CST and VS in dogs with traumatic bone frac-
tures before and after morphine administration and in 
the healthy dogs are shown in Table 3.
The CMPS-SF scores in healthy dogs were zero whereas 
in dogs with bone fractures before receiving morphine 
they were over 5/20 indicating pain. Prior to morphine 
administration, in dogs with traumatic bone fractures, 
CMPS-SF and OP-VAS scores were significantly higher 
than in healthy dogs (p < 0.0001). After morphine admin-
istration, in dogs with fractures, the CMPS-SF and OP-
VAS scores were significantly decreased compared to 
before morphine administration (p  =  0.005 and 0.02, 
respectively), however, scores were significantly higher 
compared to healthy dogs (p < 0.0001).
Saliva and blood S-VAS scores in dogs with fractures 
were significantly lower than the healthy dogs, both 
before (p = 0.048 for saliva S-VAS and p = 0.02 for blood 
S-VAS) and after morphine administration (p  =  0.002 
for saliva S-VAS and p = 0.0005 for blood S-VAS). Saliva 
and blood S-VAS scores were significantly decreased in 
dogs with fractures after morphine administration com-
pared to before (p = 0.02 for saliva S-VAS and p = 0.01 
for blood S-VAS).
In dogs with fractures, body temperature and heart 
rate significantly decreased after morphine administra-
tion compared to before (p = 0.0008 for temperature and 
p < 0.0001 for heart rate) and in healthy dogs (p < 0.0001 
for both temperature and heart rate). Temperature and 
heart rate did not significantly differ between healthy 
dogs and dogs with fractures prior to morphine adminis-
tration. Respiratory rate did not differ significantly at any 
time point.
Prior to morphine administration, in dogs with trau-
matic bone fractures, serum cortisol concentrations were 
significantly lower than healthy dogs (p =  0.01). Serum 
cortisol concentrations in dogs with fractures, before 
morphine administration, and in healthy dogs did not 
differ significantly after morphine administration.
Plasma CST concentrations, in dogs with fractures 
both before (p = 0.009) and after (p = 0.002) morphine 
administration, were significantly lower compared to 
healthy dogs. No significances in plasma CST concen-
trations were found between before and after morphine 
administration. Plasma VS did not differ significantly at 
any time point. The volume of saliva was insufficient for 
analysis of both CgA epitopes in the dogs with traumatic 
bone fractures, and saliva CST could only be analyzed 
in 12 of the samples from healthy dogs. Therefore, saliva 
CST and VS could not be compared between these two 
dog groups.
As previously stated, the dogs were allocated into four 
groups according to analgesia received before participa-
tion as follows; no analgesia (n = 3), unknown/not speci-
fied analgesia (n  =  3), carprofen (n  =  4), or morphine 
(n =  4) (Table  2). Dogs that had not received any anal-
gesia before inclusion had initially significantly lower 
serum cortisol concentrations (p  =  0.02) compared to 
Table 2 Previous analgesia received, duration of bone fractures, withdrawal period after previous analgesia, and cortisol 
concentration
Prior to inclusion, dogs with bone fractures were allocated into four groups according to analgesia received before participation (minimum 6 h withdrawal period 
prior to first sampling) as indicated above. Data presented as mean ± SD of serum cortisol concentration and mean, median (individual data) of duration of bone 
fractures and analgesia withdrawal period
a No analgesia received
b No available information of type of drug and dose
c Dogs received carprofen 2.2 mg/kg twice daily to 4.4 mg/kg once daily subcutaneous or orally
d Dogs received morphine 0.5 mg/kg intramuscular or subcutaneous
Analgesia group Duration of bone fractures (hours) Analgesia withdrawal period (hours) Cortisol concentration (nmol/L)
Nonea (n = 3) 24, 24 (1, 24, 48) 18.1 ± 22.6
Unknownb (n = 3) 48, 48 (25, 48, 72) 22, 24 (15, 24, 28) 99.4 ± 48.0
Carprofenc (n = 4) 62, 60 (30, 48, 72, 96) 21, 21 (12, 18, 24, 28) 157.3 ± 41.5
Morphined (n = 4) 47, 36 (18, 24, 48, 96) 14, 16 (6, 13, 19, 19) 133.0 ± 69.3
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dogs in the other analgesia groups, whereas no significant 
difference was found between the unknown, carprofen, 
and morphine analgesia groups (Fig. 2). Plasma CST con-
centrations did not differ (p = 0.31) between the differ-
ent analgesia groups (Fig. 3). There were no significantly 
changes in concentrations of serum cortisol and plasma 
CST before and after morphine administration regardless 
of analgesia group (Figs. 2, 3). The absolute delta values 
for serum cortisol and plasma CST did not significantly 
correlated with analgesia group or with the delta values 
of OP-VAS. The absolute delta values for plasma CST, 
however, significantly correlated with the delta values for 
CMPS-SF (p =  0.04, r =  0.31) (Fig.  4). Cause of injury, 
duration of fracture, site and number of bone fractures, 
and withdrawal period from previous analgesia had no 
effect on any of the investigated variables in the study.
Discussion
In this study, dogs with traumatic fractures of the hind 
limbs or pelvis exhibited increased pain, compared to the 
control dogs, as measured by the CMPS-SF and OP-VAS. 
The pain was reduced after morphine administration. 
Although both circulating cortisol and CST levels dif-
fered significantly between the injured and healthy dogs 
in this study, no significant change was detected after 
morphine administration and plasma CST levels over-
lapped with the previously established normal range [48].
The significantly higher subjective pain scores seen 
in dogs with traumatic bone fractures compared to the 
control dogs was an expected finding because pain and 
stress can induce behavioral changes [7, 8, 53]. The dogs 
with fractures had an average CMPS-SF score of ≥5/20 
and OP-VAS over 40 mm, which, according to what has 
previously been reported, indicates pain and the need for 
additional analgesic treatment [11, 54]. Surprisingly, the 
S-VAS scores measured during collection of saliva and 
blood samples were significantly lower in dogs with trau-
matic bone fractures compared to the healthy dogs. The 
S-VAS scores used, however, were based on avoidance 
behavior during sample collection and thus the decreased 
avoidance behavior seen in the dogs with fractures in this 
study may reflect the dog’s general condition more than 
experienced stress and pain.
The subjective pain assessments decreased significantly 
after morphine administration indicating decreased pain 
perception. The level of pain may have been underesti-
mated because of the sedative effect of morphine affect-
ing some of the parameters [54, 55]. However, despite 
receiving morphine analgesia, the subjective pain assess-
ment scores were still higher in dogs with fractures than 
Table 3 Pain assessment results in 14 dogs with bone fractures and 30 healthy dogs
CMPS-SF short form of the Glasgow composite measure pain scale, OP-VAS score of visual analog scale for overall pain, S-VAS stress behavior visual analog scale during 
saliva and blood sampling. Significantly different using Tukey adjustment when p < 0.05
a Levels significantly differed in dogs with bone fractures and healthy dogs (between healthy dogs and dogs with fractures before morphine treatment, p < 0.0001, 
p < 0.0001, p = 0.048, and p = 0.02 for CMPS-SF, OP-VAS, saliva and blood sampling S-VAS, respectively, and between healthy dogs and dogs with fractures after 
morphine treatment, p < 0.0001, p < 0.0001, p = 0.002, and p = 0.0005 for CMPS-SF, OP-VAS, saliva and blood sampling S-VAS, respectively), and also before and after 
morphine administration (p = 0.045, p = 0.02, p = 0.02, and p = 0.01 for CMPS-SF, OP-VAS, saliva and blood sampling S-VAS, respectively)
b Temperature in dogs with bone fractures after morphine administration differed significantly from either before morphine administration (p = 0.0008) or healthy 
dogs (p < 0.0001). No difference was found between dogs with fracture before morphine administration and healthy dogs
c Heart rate in dogs with bone fractures after morphine administration differed significantly from before morphine administration (p = 0.001). No difference was 
found between healthy dogs and dogs with fracture before and after morphine administration
d Serum cortisol levels in dogs with fractures before morphine injection differed significantly from healthy dogs (p = 0.01). No difference was found between dogs 
with fractures before and after morphine treatment and between after morphine treatment and healthy dogs
e Plasma catestatin levels in dogs with bone fractures before (p = 0.009) and after morphine administration (p = 0.002) differed significantly from levels in healthy 
dogs. No difference was found between before and after morphine administration in the dogs with fractures
Parameters Healthy dogs (n = 30) Traumatic bone fracture dogs (n = 14)
Before morphine After morphine
The CMPS‑SF (/20)a 0 5.9 ± 2.6 3.9 ± 2.1
OP‑VAS (mm)a 0 40.1 ± 13.7 33.3 ± 12.8
Saliva sampling S‑VAS (mm)a 41.6 ± 23.5 28.1 ± 10.6 20.3 ± 7.6
Blood sampling S‑VAS (mm)a 37.7 ± 22.1 22.0 ± 11.6 14.2 ± 9.3
Temperature (°C)b 38.9 ± 0.4 38.7 ± 0.5 38.1 ± 0.5
Heart rate (beats/minute)c 123.9 ± 30.6 137.1 ± 32.9 108.6 ± 24.3
Respiratory rate (breaths/minute) 92.6 ± 63.3 100.9 ± 59.6 117.9 ± 63.3
Serum cortisol (nmol/L)d 174.6 ± 78.5 108.1 ± 69.0 130.9 ± 93.6
Plasma catestatin (nmol/L)e 0.76 ± 0.17 0.61 ± 0.15 0.58 ± 0.16
Plasma vasostatin (nmol/L) 1.12 ± 2.16 0.39 ± 0.12 0.39 ± 0.07
Page 7 of 10Srithunyarat et al. BMC Res Notes  (2017) 10:129 
in the healthy dogs, indicating a suboptimal analgesic 
effect. Traumatic bone fractures may require multi-
modal analgesia and single morphine injections are often 
insufficient [2, 5, 56, 57]. The administration route and 
circulatory competency of the patient may affect the bio-
availability of morphine sulfate. Peak plasma concentra-
tions of morphine sulfate, after intramuscular injection 
in dogs, has been shown to occur within 5  min with a 
half-life of 82  min [56], and our samples were collected 
within this interval. Because none of the dogs in our 
study showed any clinical signs of circulatory incompe-
tence, the finding of inadequate pain relief in this study 
was probably an effect of dosage, i.e. a too low dose 
administered. These findings illustrate the importance 
of repeated pain assessments during the convalescent 
period to be able to adjust the analgesic therapy based on 
what is needed.
Routinely measured physiological parameters, such as 
body temperature, heart rate, and respiratory rate were 
similar in dogs with bone fractures and in the healthy 
dogs in this study. This was an unexpected finding; how-
ever, these physiological parameters are unspecific and 
can be affected by many factors such as environmen-
tal temperature and various surrounding stressful con-
ditions like a visit to a veterinary clinic [15, 16]. Body 
temperature and heart rate decreased significantly after 
morphine administration. This could indicate reduced 
pain levels, but morphine may have side-effects such as 
cardiovascular and respiratory depression, hypothermia, 
Fig. 2 Serum cortisol in 30 healthy and 14 dogs with fractures before 
and after morphine administration. *Dogs without previous anal‑
gesia (None, n = 3) prior to inclusion to the study had significantly 
(p = 0.02) lower cortisol concentration than dogs in the other anal‑
gesia groups. No significant difference was found between unknown 
(Unknown, n = 3), carprofen (Carprofen, n = 4), or morphine (Mor‑
phine, n = 4) analgesia groups. No significant difference in cortisol 
concentration was found between before (Before) and after (After) 
morphine administration in dogs with traumatic bone fractures 
(n = 14). The upper vertical line (whisker) refers to maximal value and 
lower whisker refers to minimal value. The length of the box refers to 
interquartile range from quartile 1–3 (percentile 25–75) where the top 
of the box is quartile 3 and the bottom is quartile 1. The circle symbol 
in the box refers to mean and the horizontal line in the box is median
Fig. 3 Plasma catestatin in 30 healthy and 14 dogs with fractures 
before and after morphine administration. No significant differ‑
ence was found between the analgesia groups (None, Unknown, 
Carprofen, Morphine) or when compared before (Before) and after 
(After) morphine administration in the dogs with traumatic bone 
fractures. The upper vertical line (whisker) refers to maximal value and 
lower whisker refers to minimal value. The length of the box refers to 
interquartile range from quartile 1–3 (percentile 25–75) where the top 
of the box is quartile 3 and the bottom is quartile 1. The circle symbol 
in the box refers to mean and the horizontal line in the box is median
Fig. 4 Absolute delta values for plasma catestatin concentrations 
in relation to delta values for CMPS‑SF. In dogs with bone fractures 
(n = 14), the absolute delta values for plasma catestatin correlated 
significantly to the delta values for CMPS‑SF (p = 0.04, r = 0.31). Dogs 
with lower delta values for CMPS‑SF scores, indicating good pain 
relief, had higher absolute delta values for plasma catestatin. CMPS-SF 
the short form of Glasgow composite measure scale
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hypotension, sedation, anxiety, and bradycardia [58] 
which further illustrates the limitation of these physi-
ological parameters for monitoring pain.
In the present study, cortisol concentrations were sig-
nificantly lower in dogs with traumatic bone fractures 
prior to morphine administration compared to the 
healthy dogs. Furthermore, when comparing the differ-
ent initial analgesic groups, cortisol concentrations in 
the dogs that had not received analgesia before inclu-
sion were significantly lower than in the dogs that had 
received analgesia prior to inclusion. These results may 
reflect a downregulation of the HPA axis caused by long-
standing pain in the dogs with fractures, leading to sub-
sequent low concentrations of cortisol, which has been 
shown previously in studies of chronic pain and stress 
disorders [20, 59–61].
After morphine administration, the absolute delta 
values for and concentrations of cortisol did not change 
significantly. It was initially expected that cortisol con-
centration would normalize after morphine analgesia 
[59, 62], however, the CMPS-SF and OP-VAS, as stated 
previously, indicated suboptimal analgesia obtained 
in the dogs with fractures. In addition, there are other 
potential contributing factors that may influence the 
serum cortisol concentrations. For example, the epi-
sodic and pulsatile secretion of cortisol which limits 
the usefulness of a single measurement of plasma cor-
tisol because it is unknown if the sampling is taken 
at a peak or trough in plasma cortisol concentrations 
[18–20, 63]. Psychologically induced stress from being 
kept at the animal clinic may also limit serum cortisol’s 
usefulness as a pain biomarker in a clinical setting [15, 
16, 64, 65].
Plasma VS concentrations did not change significantly 
between any time points in this study, whereas plasma 
CST concentrations, similar to serum cortisol, were sig-
nificantly lower in dogs with traumatic bone fractures 
compared to the healthy control group. Catestatin has 
an inhibitory role as a negative feedback for the release 
of catecholamines and CgA [66], which may contribute 
to the decreased concentrations of plasma CST seen in 
this study. Decreased concentrations of CST have also 
been reported in dogs after ovariohysterectomy [46]. 
Dogs with lower delta values for CMPS-SF scores, indi-
cating good pain relief, had higher absolute delta values 
for plasma CST. Although the absolute delta values for 
plasma CST correlated significantly to the delta values 
for CMPS-SF, the correlation was very weak and plasma 
CST and VS concentrations overlapped to a large degree 
with previously established normal ranges in dogs. In 
addition, cause of injury, duration of fracture, site and 
number of bone fractures, and withdrawal period from 
previous analgesia did not significantly affect plasma 
CST and VS concentrations in this study. In conclusion, 
although requiring further controlled experimental stud-
ies, repeated sampling of plasma CST may be of interest 
for evaluating pain progression within the same patient. 
However, the large degree of overlap with normal values 
indicates that plasma CST has limited potential as a sin-
gle clinical biomarker for pain induced stress in dogs. In 
addition, our results showed that plasma VS is not useful 
for this purpose.
This study was performed as a clinical trial and sev-
eral limitations should be addressed. Ideally, all dogs 
should have had the same type of fractures and duration 
of injury, however, because studies on pain in a clinical 
situation are difficult to standardize, this was not possi-
ble. However, in agreement with the 3Rs (replace, reduce, 
refine) for ethical use of animals in research, we chose to 
perform this first study on CST and VS’s potentials in a 
clinical setting despite these difficulties. By first inves-
tigating the potential of CST and VS as biomarkers in 
injured patients admitted to an animal hospital for treat-
ment, we may reduce the need for unnecessary painful 
experimental studies.
As no data on these biomarkers were available in dogs 
with acute pain prior to this study, we were not able to 
determine sample size beforehand which was a limita-
tion. This study was therefore designed as a cross sec-
tional study. The control dogs included in this study were 
all intact females which is a limitation because gender 
may affect neuroendocrine secretion i.e. cortisol. How-
ever, we have previously shown that CST and VS are not 
affected by gender [48]. Samples should ideally have been 
collected in dogs of similar age, gender, and at the same 
time of day, which was not possible in a clinical setting 
within a reasonable time span. It would have been pref-
erable if sedation scores had been evaluated. Subjec-
tive pain and stress assessment should be performed by 
a trained single observer as in this study [67], however, 
a blinded observer would have been preferable in order 
to reduce confounding effects. The episodic secretion of 
cortisol might be a confounding factor, however, whether 
or not there is a circadian variation in dogs is still con-
troversial [18, 19]. Concentrations of CST and VS have 
previously been reported to be unaffected by age, gender, 
breed, and time of collection [48]. Several factors such as 
variations in the duration and severity of injury, previous 
analgesia administered, the analgesia withdrawal period, 
individual variation, and psychological stress may also 
affect the findings reported here [15, 62]. However, val-
ues of CST and VS overlapped to a large degree with the 
ranges previously established in healthy dogs accustomed 
to the sample procedure regardless of fracture, previous 
analgesia, and duration of injuries, and by the CMPS-SF 
and OP-VAS indicating pain. Our results, therefore, show 
Page 9 of 10Srithunyarat et al. BMC Res Notes  (2017) 10:129 
that the potential of these CgA epitopes as biomarkers for 
pain-induced stress in dogs is limited in a clinical setting.
Conclusions
Measurement of circulating cortisol and CST, as well 
as the CMPS-SF, OP-VAS, S-VAS scores, were used for 
pain assessment in dogs with traumatic bone fractures. 
Subjective, but not objective assessments, indicated that 
intramuscular morphine administration resulted in par-
tially reduced pain in dogs with bone fractures. Plasma 
CST and VS remained to a large degree within the estab-
lished reference ranges throughout the study indicating 
their limited use as biomarkers for pain-induced stress in 
dogs in this clinical setting.
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